ERBB2 and breast cancer: The development of HER2-targeted therapies using monoclonal antibodies (mAb), such as trastuzumab and pertuzumab and tyrosine kinase inhibitors, such as lapatinib, has significantly improved the survival of patients with HER2+ BC.